BPC-157 + TB-500 Stack
BPC-157 + TB-500 Recovery Stack Protocol
Research Parameters
- Typical Dose Range
- BPC-157: 250 to 500 mcg daily subcutaneous (split AM/PM or near injury site). TB-500: 2 to 2.5 mg twice weekly (loading); 2 mg weekly (maintenance). Protocol duration: loading 4 to 6 weeks, maintenance 2 to 4 weeks, wash-out minimum 2 to 4 weeks before re-running.
- Half-Life
- BPC-157: ~4 hours. TB-500: ~2 to 3 hours (peptide); biological effects persist longer.
- Administration Route
- Subcutaneous, Intramuscular
Dosing information is for research purposes only and has not been evaluated by the FDA.
This is the recovery stack. The peptide combination researchers return to most often for serious soft tissue injury, chronic tendon issues, and training-limiting joint problems. Neither peptide alone is as well-researched in stacked form as the combination is in the peptide research literature, which is unusual. The reason they work together rather than compete: totally different mechanisms, complementary targets.
BPC-157 is the local healer. It drives new blood vessel formation at the injury site and activates growth hormone receptors in damaged tissue. TB-500 is the systemic mobilizer. It travels through the body and gets reparative cells to where they need to be. Research protocols run the stack in a loading phase for 4 to 6 weeks, a maintenance phase for 2 to 4 weeks, then a wash-out. Treating the stack as a protocol rather than a perpetual supplement is what the literature consistently supports.
For research purposes only.
Mechanism of Action
This is two peptides acting on different phases of tissue repair. BPC-157 drives localized angiogenesis and upregulates local growth factor receptors. TB-500 upregulates actin, enabling cell migration across the body. The combination addresses both the local rebuilding environment and the systemic supply of reparative cells. Compatible outputs from distinct inputs.
Citations
Frequently Asked Questions
- Why stack BPC-157 and TB-500 instead of running them separately?
Because the mechanisms complement rather than duplicate. BPC-157 builds local blood supply; TB-500 mobilizes reparative cells systemically. Research suggests the combination produces more complete repair than either peptide alone, particularly in poorly vascularized tissue like tendons. For research purposes only.
- Can the stack be run indefinitely?
Research protocols do not support indefinite use. The literature centers on loading-maintenance-washout cycling because the peptides drive active repair processes that benefit from defined start and end points. For research purposes only.
- What's the difference between this stack and running GHK-Cu with either?
GHK-Cu is a collagen and extracellular matrix signal. It supports the rebuilding material. BPC-157 and TB-500 drive cellular migration and angiogenesis. They support the rebuilding process. Some research protocols add GHK-Cu to the stack; others run it sequentially. For research purposes only.